LAMA/LABA Combination, Inhalers
PDL Reference Documents
- Inhalers for Asthma and COPD - Feb 01, 2024
- Inhalers for Asthma/COPD - Dec 01, 2022
- Asthma and COPD maintenance medications - Oct 01, 2020
- Asthma and COPD Maintenance Medications - May 23, 2019
- Class Scan: Asthma and COPD - Jan 25, 2018
- Drugs to Treat Asthma and Chronic Obstructive Pulmonary Disease (COPD) - Sep 29, 2016
- Asthma and COPD - Sep 24, 2015
Newsletters
PDL Status Values
Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the
Non-Preferred Drugs in Select PDL Classes prior authorization criteria.
New drugs will be listed as N until reviewed by the P&T Committee and are subject to the
New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.
To request a Prior Authorization, please use this form.
| Generic Name | Brand Name | Form | PDL Status |
Current Drug Use Criteria | New Drug Evaluation |
|---|---|---|---|---|---|
| tiotropium Br/olodaterol HCl | STIOLTO RESPIMAT | MIST INHAL | Y | ||
| umeclidinium brm/vilanterol tr | ANORO ELLIPTA | BLST W/DEV | Y | ||
| aclidinium brom/formoterol fum | DUAKLIR PRESSAIR | AER POW BA | N | PA Document | |
| budesonide/glycopyr/formoterol | BREZTRI AEROSPHERE | HFA AER AD | N | PA Document | |
| fluticasone/umeclidin/vilanter | TRELEGY ELLIPTA | BLST W/DEV | N | PA Document | |
| glycopyrrolate/formoterol fum | BEVESPI AEROSPHERE | HFA AER AD | N | PA Document |